Prokhorova et al. showed significant differences in pre-treatment GDH activity between subgroups of patients with a first episode of psychosis (FEP), chronic patients and controls, through which they concluded that baseline levels of platelet GDH activity may be important in predicting the efficacy of antipsychotic pharmacotherapy in patients with FEP [220]. This evidence concerns the gene GLUD1 and psychotic disorder.